Symptoms mirror Omicron’s, that is, fever, cough, fatigue, sore throat, and muscle aches. Though India’s Covid response ...

A Wall Street maxim states, “Twenty percent of investors who want to make money are in stocks, while the other 80 percent who ...

A widely available antiviral medication offers new possibilities for long Covid patients seeking relief from debilitating ...

A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

Encounter-level factors played a key role in limiting outpatient COVID-19 treatment for Black and Latino patients.

Value stocks are generally companies that trade at a price lower than their fundamental value or what their performance ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent ...

Three supercharged dividend stocks have the necessary catalysts to make their patient shareholders notably richer.

Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting ...

Paxlovid, the five-day antiviral treatment for covid, may not reduce the risk of covid-related hospitalizations and all-cause deaths in vaccinated older adults, a new study suggests.

New research finds that Paxlovid, a COVID-19 antiviral, had minimal benefit in vaccinated older adults.